Quantcast

Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat.

Research paper by Ajai A Chari, Menaka M Bhor, Lamis L Eldjerou, Adrienne M AM Gilligan, Alyson A Urniasz, Denise D Globe, Diana D Stetsovsky, Helen H Varker, Brian B Davis, Machaon M Bonafede, James J Talcott

Indexed on: 31 May '18Published on: 31 May '18Published in: Future oncology (London, England)



Abstract

To examine real-world treatment patterns in multiple myeloma (MM) patients treated with panobinostat. Using a US claims database, MM patients treated with panobinostat during 02/01/2015-01/31/2017 were evaluated. Lines of therapy, combination regimens, dosing and duration were measured. Ninety-five patients were included (mean age: 61.4 years). Patients were heavily pretreated, with 88.4% exposed to both a proteasome inhibitor and an immunomodulatory agent. A panobinostat containing regimen was started in the fourth or more (86%) lines of therapy within a median of 3.77 years from initial treatment. The most common treatment combination was bortezomib/dexamethasone/panobinostat (31.6%) with 69.5% receiving the recommended dose (20 mg). Mean duration was 98.8 days. Patients received the recommended dose, most commonly with bortezomib and dexamethasone. Panobinostat was used in heavily pretreated patients within 4 years post-diagnosis, reflecting an advanced MM population.

More like this: